E-mail This Site

E-mail information about FASLODEX

If you would like to send information about this site to a colleague or a patient, just complete the form below and click "Submit." Your contact will receive an e-mail with a direct URL link to this site.

Your e-mail address and the e-mail address of your recipient will be used for transmission only and will not be used for any other purposes. Review our complete Privacy Policy.

Enter the following information and click “Submit.”

* Your e-mail address:

* Your colleague's or patient's e-mail address:

A A AText Resize
Share

Register for the Hormonal Aspects of Breast Cancer Web-based Lecture Series Video lectures from experts in the hormonal treatment of metastatic breast cancer

Request a Rep Request to have an AstraZeneca representative contact you

Important Information About FASLODEX

FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Important Safety Information About FASLODEX

FASLODEX is only for postmenopausal women. FASLODEX can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised not to become pregnant while receiving FASLODEX. (See CONTRAINDICATIONS and WARNINGS sections of full Prescribing Information.)
Because FASLODEX is administered intramuscularly, it should not be used in patients with bleeding diatheses, thrombocytopenia, or in patients on anticoagulants.
In clinical trials, the most commonly reported adverse effects seen with FASLODEX, regardless of the investigator’s assessment of causality, were gastrointestinal symptoms (nausea 26.0%, vomiting 13.0%, constipation 12.5%, diarrhea 12.3%, abdominal pain 11.8%), headache 15.4%, back pain 14.4%, hot flashes 17.7%, and pharyngitis 16.1%. Injection site reactions with mild, transient pain and inflammation were reported in 7% of patients (1% of treatments) given a single 5 mL injection and 27% of patients (4.6% of treatments) given 2 x 2.5 mL injections of FASLODEX.

Please click here for full Prescribing Information.

This product information is intended for US health care professionals only.